Pedro Henrique Reis-Barbosa (Pedro H Reis-Barbosa)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Tyrosine Kinase

Systemic Lupus Erythematosus

High Fat Diet Induced

Top Venues

Diabetes, obesity & metabolism

Journal of gastroenterology and hepatology

Fundamental & clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Pedro Henrique Reis-Barbosa, Carlos Alberto Mandarim-de-Lacerda
Sodium-glucose cotransporter-2 inhibitor (SGLT2i) plus glucagon-like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase-4 inhibitor combination in treating obese mice metabolic dysfunction-associated steatotic liver disease (MASLD). Fundamental & clinical pharmacology (2024)
Pedro Henrique Reis-Barbosa, Marcia Barbosa Aguila, Carlos Alberto Mandarim-de-Lacerda
Tirzepatide, a dual receptor agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1, enhances β-cell survival and maintenance markers in obese diabetic ovariectomized mice. Diabetes, obesity & metabolism (2024)
Pedro Henrique Reis-Barbosa, Ilitch Aquino Marcondes-de-Castro, Thatiany Souza Marinho, Marcia Barbosa Aguila, Carlos Alberto Mandarim-de-Lacerda
The dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice. Diabetes, obesity & metabolism (2024)
Ilitch Aquino Marcondes-de-Castro, Pedro Henrique Reis-Barbosa, Thatiany Souza Marinho, Marcia Barbosa Aguila, Carlos Alberto Mandarim-de-Lacerda
AMPK/mTOR pathway significance in healthy liver and non-alcoholic fatty liver disease and its progression. Journal of gastroenterology and hepatology (2023)